Publication: Population Pharmacokinetics of Polymyxin B
Issued Date
2018-09-01
Resource Type
ISSN
15326535
00099236
00099236
DOI
Other identifier(s)
2-s2.0-85052211010
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Pharmacology and Therapeutics. Vol.104, No.3 (2018), 534-538
Suggested Citation
Pooja Manchandani, Visanu Thamlikitkul, Yanina Dubrovskaya, Jessica T. Babic, David C. Lye, Lawrence S. Lee, Vincent H. Tam Population Pharmacokinetics of Polymyxin B. Clinical Pharmacology and Therapeutics. Vol.104, No.3 (2018), 534-538. doi:10.1002/cpt.981 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46417
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Population Pharmacokinetics of Polymyxin B
Abstract
© 2017 American Society for Clinical Pharmacology and Therapeutics Polymyxin B is used as a last treatment resort for multidrug-resistant Gram-negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability. Four serial blood samples each were collected from 35 adult patients at steady state. The concentrations of individual polymyxin B components were analyzed using a validated liquid chromatography / tandem mass spectrometry assay and combined to derive total concentrations. A maximum likelihood expectation maximization approach was used to fit the data. Various demographic variables were investigated as potential covariates for clearance and volume of distribution (Vd) using linear regression analysis. A one-compartment model fit to the data satisfactorily (r2 = 0.96). The best-fit mean ± SD for clearance and Vd were 2.5 ± 1.1 L/h and 34.3 ± 16.4 L, respectively. Creatinine clearance was found to be a statistically significant covariate of clearance, but the magnitude was deemed clinically insignificant.